top of page

Free On-Demand Webinar:
👉 Strategic CMC for Biotech & Pharma: How to Avoid Costly FDA Delays

CMC Drug Development Tips

Characterization of Impurities (Later IND Phases)

Nexus CMC Advisors
Characterization of Impurities (Later IND Phases)
Characterization of Impurities (Later IND Phases)

Characterization of Impurities (Later IND Phases)

00:36
Control of Materials (Early Phase IND)

Control of Materials (Early Phase IND)

00:40
Stability Failure - Panic vs. Strategy

Stability Failure - Panic vs. Strategy

01:00
Particle Size Shift - Strategy vs. Reaction

Particle Size Shift - Strategy vs. Reaction

01:00
Intro to CMC for Peptide Therapeutics
03:29
IND CMC Information
00:17
Phase Appropriate CMC Content
00:16
IND Common Pitfalls
00:16
Balancing Regulatory Requirements with Flexibility
00:16

© 2024-Present by Nexus CMC Advisors LLC.

bottom of page